SÃ©bastien Anguille

List of Publications by Year
in descending order

45 papers	2,623 citations	236925 25 h-index	243625 44 g-index
46 all docs	46 docs citations	46 times ranked	3964 citing authors

#	Article	IF	Citations
1	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. Frontiers in Immunology, 2022, 13, 734256.	4.8	2
2	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Journal of Translational Medicine, 2022, 20, 124.	4.4	21
3	Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. Cancer Immunology, Immunotherapy, 2022, 71, 2801-2814.	4.2	3
4	Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.. Journal of Clinical Oncology, 2022, 40, 8029-8029.	1.6	11
5	The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. Pharmaceutics, 2021, 13, 396.	4.5	18
6	Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia. Cancers, 2021, 13, 4519.	3.7	2
7	CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy. Blood, 2021, 138, 2910-2910.	1.4	11
8	Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics. Journal of Clinical Medicine, 2020, 9, 3090.	2.4	8
9	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 164.	17.0	88
10	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 2020, 12, 194.	4.5	40
11	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. Cancers, 2020, 12, 256.	3.7	12
12	Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma. Blood, 2020, 136, 27-28.	1.4	6
13	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Frontiers in Immunology, 2019, 10, 1613.	4.8	70
14	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. Cancers, 2019, 11, 1029.	3.7	7
15	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. Cancers, 2019, 11, 1396.	3.7	13
16	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. Journal of Clinical Medicine, 2019, 8, 579.	2.4	48
17	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. Frontiers in Immunology, 2018, 9, 658.	4.8	38
18	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood, 2017, 130, 1713-1721.	1.4	170

#	Article	IF	Citations
19	Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Oncotarget, 2017, 8, 13652-13665.	1.8	18
20	Generation and Cryopreservation of Clinical Grade Wilmsâ€™ Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. Methods in Molecular Biology, 2016, 1393, 27-35.	0.9	6
21	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. Journal of Hematology and Oncology, 2016, 9, 101.	17.0	96
22	Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. , 2016, 158, 24-40.		158
23	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. Oncotarget, 2016, 7, 73960-73970.	1.8	17
24	Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS ONE, 2015, 10, e0123340.	2.5	47
25	Engineering monocyte-derived dendritic cells to secrete interferon-Î± enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunology, Immunotherapy, 2015, 64, 831-842.	4.2	27
26	Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy. OncoImmunology, 2015, 4, e1021538.	4.6	53
27	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacological Reviews, 2015, 67, 731-753.	16.0	129
28	Transpresentation of interleukin-15 by IL-15/IL-15RÎ± mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget, 2015, 6, 44123-44133.	1.8	39
29	HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV â€positive tumour cells. Journal of Cellular and Molecular Medicine, 2014, 18, 1372-1380.	3.6	16
30	Tumoricidal activity of human dendritic cells. Trends in Immunology, 2014, 35, 38-46.	6.8	62
31	Clinical use of dendritic cells for cancer therapy. Lancet Oncology, The, 2014, 15, e257-e267.	10.7	565
32	Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients. Blood, 2014, 124, 310-310.	1.4	5
33	CD56 marks human dendritic cell subsets with cytotoxic potential. OncoImmunology, 2013, 2, e23037.	4.6	29
34	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2013, 9, 1956-1961.	3.3	28
35	Interferon Î± may be back on track to treat acute myeloid leukemia. OncoImmunology, 2013, 2, e23619.	4.6	33
36	Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood, 2012, 120, 3936-3944.	1.4	80

#	Article	IF	Citations
37	Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy, 2012, 14, 647-656.	0.7	49
38	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PLoS ONE, 2012, 7, e51851.	2.5	48
39	Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC. PLoS ONE, 2011, 6, e20952.	2.5	31
40	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. Hum Vaccin, 2011, 7, 579-584.	2.4	30
41	Induction of complete and molecular remissions in acute myeloid leukemia by Wilmsâ€™ tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13824-13829.	7.1	341
42	Identification of a hypertrophied bronchial artery using three-dimensional computed tomography. European Journal of Cardio-thoracic Surgery, 2009, 36, 764-764.	1.4	1
43	Dendritic Cell-Based Cancer Gene Therapy. Human Gene Therapy, 2009, 20, 1106-1118.	2.7	68
44	Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. Journal of Translational Medicine, 2009, 7, 109.	4.4	74
45	Sore throat: a trivial complaint masking a lifeâ€threatening condition. Medical Journal of Australia, 2009, 190, 454-456.	1.7	0